Indivior (NASDAQ:INDV) Releases Earnings Results, Hits Estimates

Indivior (NASDAQ:INDV - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.32 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.32, Zacks reports. The firm had revenue of $298.00 million during the quarter, compared to analysts' expectations of $262.35 million. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. Indivior updated its FY 2025 guidance to EPS.

Indivior Trading Down 5.8 %

INDV traded down $0.53 during trading on Friday, hitting $8.47. 1,744,924 shares of the company's stock traded hands, compared to its average volume of 1,204,704. The company's 50 day simple moving average is $11.51 and its two-hundred day simple moving average is $10.87. Indivior has a 12-month low of $7.33 and a 12-month high of $23.22. The stock has a market capitalization of $1.17 billion, a price-to-earnings ratio of -211.57 and a beta of 0.73.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Rodman & Renshaw assumed coverage on Indivior in a research report on Tuesday, January 28th. They set a "buy" rating and a $16.00 price target for the company. RODMAN&RENSHAW raised Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $16.00 price target (up previously from $15.00) on shares of Indivior in a research report on Friday, October 25th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.